MedTrace Logo

Hyoscine Butylbromide Effect on Duration of Labor

NCT03441217 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 218

Last updated 2019-12-06

No results posted yet for this study

Summary

To evaluate the duration of labour (active phase of labour) in nulliparous women with gestations between 37 and 41 6/7 weeks when 20 mg of Hyoscine butylbromide was applied intravenously and compared with similar patients that received a placebo.

Conditions

  • Labor

Interventions

DRUG

Hyoscine Butylbromide 20Mg/1mL Injection

Nulliparous women with gestations at term receive 20 mg of Hyoscine butylbromide upon arrival in the Labor and Delivery Unit (4-5 cms).

DRUG

Saline Solution

Nulliparous women with gestations at term receive 20 mg of saline solution upon arrival in the Labor and Delivery Unit (4-5 cms).

Sponsors & Collaborators

  • Sistema Nacional de Investigadores de Panamá

    collaborator UNKNOWN

  • Saint Thomas Hospital, Panama

    lead OTHER

Principal Investigators

  • Osvaldo Reyes, MD · Maternidad del Hospital Santo Tomás

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-12
Primary Completion
2019-08-30
Completion
2019-11-30

Countries

  • Panama

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03441217 on ClinicalTrials.gov